Search - tctmd.com

Displaying 501 - 520 of 609

Sort: Relevancy | Date

News Daily News

Bigger Primary PCI Centers May Be Better, Danish Study Suggests

Yael L. Maxwell

December 28, 2014

Presentation

New Ischemic Stroke and Outcomes With Vorapaxar vs Placebo

Presenter: B.P. Bonaca

December 02, 2014

News Conference News AHA 2014

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

November 16, 2014

News Daily News

血压大幅下降似乎能够安全降低CAD患者的卒中风险

Todd Neale

November 02, 2014

News Daily News

Substantial BP Reductions Appear to Lower Stroke Risk Safely in CAD Patients

Todd Neale

November 02, 2014

News Features TCT 2014

Thoughtful Insights at TCT: Tackling Resistant Hypertension, Long SFA Lesions, and Complex Carotid Disease

Todd Neale

October 31, 2014

Presentation

Systolic and Diastolic BP Changes in Relation with MI and Stroke in Patients With CAD

Presenter: Paolo Verdecchia

October 29, 2014

News Conference News TCT 2014

Symplicity Flex: No Benefit of Renal Denervation in Mild Resistant Hypertension

September 16, 2014

News Industry News

Randomized Sham-Controlled Trial Examines Blood Pressure Effects of Renal Denervation in Patients with Mild Refractory Hypertension

September 16, 2014

News Industry News

New Study Evaluates the Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in Patients with Coronary Artery Disease

September 16, 2014

News Conference News TCT 2014

Experts Debate Future of Renal Denervation

September 16, 2014

News Conference News TCT 2014

SYMPLICITY HTN-3 Substudy Examines BP Response Factors in African Americans

Yael L. Maxwell

September 15, 2014

News Conference News TCT 2014

TCT Keynote: Global Vision for Prevention in Children and Adults Could Change CVD Landscape

September 14, 2014

News Conference News TCT 2014

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

September 13, 2014

News Conference News TCT 2014

Experts Debate Future of Renal Denervation Therapy

September 13, 2014

News Daily News

High Reactivity on Aspirin Just Before PCI Linked to Worse Outcomes

September 02, 2014

News Conference News ESC 2014

Observational Studies Ask How Much Medication Adherence Matters After MI

Caitlin E. Cox

August 31, 2014

News Features

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

June 24, 2014

News Features

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

June 18, 2014

News Daily News

SYMPLICITY HTN-2: Renal Denervation Safe, Effective at 3 Years

Yael L. Maxwell

June 11, 2014

Advertisement

Bigger Primary PCI Centers May Be Better, Danish Study Suggests

New Ischemic Stroke and Outcomes With Vorapaxar vs Placebo

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

血压大幅下降似乎能够安全降低CAD患者的卒中风险

Substantial BP Reductions Appear to Lower Stroke Risk Safely in CAD Patients

Thoughtful Insights at TCT: Tackling Resistant Hypertension, Long SFA Lesions, and Complex Carotid Disease

Systolic and Diastolic BP Changes in Relation with MI and Stroke in Patients With CAD

Symplicity Flex: No Benefit of Renal Denervation in Mild Resistant Hypertension

Randomized Sham-Controlled Trial Examines Blood Pressure Effects of Renal Denervation in Patients with Mild Refractory Hypertension

New Study Evaluates the Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in Patients with Coronary Artery Disease

Experts Debate Future of Renal Denervation

SYMPLICITY HTN-3 Substudy Examines BP Response Factors in African Americans

TCT Keynote: Global Vision for Prevention in Children and Adults Could Change CVD Landscape

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

Experts Debate Future of Renal Denervation Therapy

High Reactivity on Aspirin Just Before PCI Linked to Worse Outcomes

Observational Studies Ask How Much Medication Adherence Matters After MI

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

SYMPLICITY HTN-2: Renal Denervation Safe, Effective at 3 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content